X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.ucb.com/stories-media/Press-Releases/article/ASBMR-2022-3D-modelling-of-hip-DXA-scans-in-postmenopausal-women-with-osteoporosis-reveals-superior-improvements-in-bone-density-of-romosozumab-versus-controls
https://www.ucb.com/stories-media/Press-Releases/article/UCB-Shares-Breadth-of-Innovative-New-Data-from-Rheumatology-Portfolio-for-EULAR-2020-E-Congress
http://investors.amgen.com/news-releases/news-release-details/amgen-reports-first-quarter-2020-financial-results/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761062
http://www.pmlive.com/pharma_news/ucbamgens_evenity_finally_cleared_for_osteoporosis_in_europe_1319792
http://www.pharmatimes.com/news/chmp_u-turn_for_evenity_1313762
https://www.prnewswire.com/news-releases/evenity-romosozumab-receives-positive-chmp-opinion-for-the-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture-300941029.html
http://www.pharmatimes.com/news/az_bags_two_extensions_in_latest_chmp_decisions_1292946
https://www.raps.org/news-and-articles/news-articles/2019/6/emas-chmp-rejects-another-drug-approved-by-us-fda
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761062
https://endpts.com/once-spurned-amgen-wins-the-fda-over-with-its-bone-building-osteoporosis-drug-evenity/
https://endpts.com/second-times-a-charm-for-osteoporosis-drug-from-amgen-ucb-as-fda-panel-grants-its-blessing/
https://www.raps.org/news-and-articles/news-articles/2019/1/fda-takes-proactive-steps-to-make-naloxone-an-otc?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2017%20January
https://endpts.com/fda-staff-largely-unfazed-by-cv-signal-in-amgen-osteoporosis-drug-trials/
https://endpts.com/fda-staff-largely-unfazed-by-cv-signal-in-amgen-osteoporosis-drug-trials/
https://www.raps.org/regulatory-focus/news-articles/2018/1/fda-advisory-committee-calendar?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%208%20January
http://www.pharmatimes.com/news/ucb,_amgen_refile_osteoporosis_drug_evenity_1244387
https://endpts.com/amgen-ucb-are-back-pitching-once-rejected-osteoporosis-drug-romo-to-the-fda-but-big-hurdles-lie-ahead/
https://www.biospace.com/article/releases/amgen-and-ucb-resubmit-biologics-license-application-bla-for-evenity-romosozumab-to-the-us-fda/?s=65
Market Place
Share 
